Free Trial

Vanguard Group Inc. Purchases 53,526 Shares of STERIS plc (NYSE:STE)

STERIS logo with Medical background

Vanguard Group Inc. increased its position in shares of STERIS plc (NYSE:STE - Free Report) by 0.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,864,606 shares of the medical equipment provider's stock after acquiring an additional 53,526 shares during the quarter. Vanguard Group Inc. owned approximately 12.01% of STERIS worth $2,608,434,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. VisionPoint Advisory Group LLC acquired a new position in shares of STERIS in the 4th quarter valued at $34,000. Pingora Partners LLC acquired a new position in shares of STERIS during the 4th quarter valued at $37,000. Glassman Wealth Services acquired a new position in shares of STERIS during the 4th quarter valued at $38,000. Spire Wealth Management lifted its holdings in shares of STERIS by 88.0% during the 4th quarter. Spire Wealth Management now owns 203 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 95 shares in the last quarter. Finally, AdvisorNet Financial Inc lifted its holdings in shares of STERIS by 144.9% during the 4th quarter. AdvisorNet Financial Inc now owns 311 shares of the medical equipment provider's stock valued at $68,000 after acquiring an additional 184 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.

STERIS Stock Up 0.2 %

STERIS stock traded up $0.38 during midday trading on Tuesday, hitting $216.50. 457,734 shares of the stock were exchanged, compared to its average volume of 491,800. STERIS plc has a 1 year low of $195.47 and a 1 year high of $254.00. The firm has a market cap of $21.40 billion, a P/E ratio of 56.68 and a beta of 0.85. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.08 and a quick ratio of 2.36. The company has a 50 day moving average price of $217.68 and a two-hundred day moving average price of $220.18.


STERIS (NYSE:STE - Get Free Report) last released its earnings results on Wednesday, May 8th. The medical equipment provider reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.41 by $0.17. The company had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.41 billion. STERIS had a net margin of 6.95% and a return on equity of 13.73%. The company's revenue was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.30 EPS. On average, sell-side analysts predict that STERIS plc will post 9.24 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 26th. Stockholders of record on Wednesday, June 12th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 0.96%. The ex-dividend date is Wednesday, June 12th. STERIS's dividend payout ratio (DPR) is presently 54.45%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. JMP Securities restated a "market outperform" rating and set a $265.00 target price on shares of STERIS in a report on Thursday, May 9th. Needham & Company LLC restated a "hold" rating on shares of STERIS in a report on Friday, May 10th. StockNews.com upgraded shares of STERIS from a "hold" rating to a "buy" rating in a report on Saturday. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $225.00 price target (up previously from $220.00) on shares of STERIS in a research note on Friday, May 10th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, STERIS currently has an average rating of "Moderate Buy" and an average target price of $241.60.

View Our Latest Research Report on STERIS

Insider Activity

In other news, SVP Cary L. Majors sold 2,024 shares of the company's stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $232.13, for a total transaction of $469,831.12. Following the completion of the transaction, the senior vice president now directly owns 11,369 shares of the company's stock, valued at $2,639,085.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Jacqueline B. Kosecoff sold 4,584 shares of the business's stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $231.53, for a total transaction of $1,061,333.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Cary L. Majors sold 2,024 shares of the business's stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $232.13, for a total value of $469,831.12. Following the transaction, the senior vice president now owns 11,369 shares of the company's stock, valued at $2,639,085.97. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,762 shares of company stock valued at $1,798,477. 1.14% of the stock is currently owned by insiders.

About STERIS

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Featured Articles

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Should you invest $1,000 in STERIS right now?

Before you consider STERIS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.

While STERIS currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines